참고문헌
- Are C, Shaha AR (2006). Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol, 13, 453-64. https://doi.org/10.1245/ASO.2006.05.042
- Campadelli-Fiume G, De Giovanni C, Gatta V, et al (2011). Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol, 21, 213-26. https://doi.org/10.1002/rmv.691
- Goldstein DJ, Weller SK (1988). Factor (s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology, 166, 41-51. https://doi.org/10.1016/0042-6822(88)90144-4
- Huang YY, Yu Z, Lin SF, et al (2007). Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab, 92, 1965-70. https://doi.org/10.1210/jc.2007-0040
- Lai ML, Faa G, Serra S, et al (2005). Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma. Arch Pathol Lab Med, 129, 55-7.
- Li J, Zeng W, Huang Y, et al (2012). Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther, 19, 707-14. https://doi.org/10.1038/cgt.2012.49
- Lin SF, Gao SP, Price DL, et al (2008). Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res, 14, 1519-28. https://doi.org/10.1158/1078-0432.CCR-07-4628
- Martuza RL, Malick A, Markert JM, et al (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252, 854-6. https://doi.org/10.1126/science.1851332
- Mohr I, Sternberg D, Ward S, et al (2001). A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol, 75, 5189-96. https://doi.org/10.1128/JVI.75.11.5189-5196.2001
- Pacini F, Castagna MG, Cipri C, et al (2010). Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol), 22, 475-85. https://doi.org/10.1016/j.clon.2010.05.002
- Reinblatt M, Pin RH, Fong Y (2007). Herpes viral oncolysis: a novel cancer therapy. J Am Coll Surg, 205, S69-75.
- Russell SJ, Peng KW, Bell JC (2012). Oncolytic virotherapy. Nat Biotechnol, 30, 658-70. https://doi.org/10.1038/nbt.2287
- Sherman SI, Wirth LJ, Droz JP, et al (2008). Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med, 359, 31-42. https://doi.org/10.1056/NEJMoa075853
- Sipos JA, Mazzaferri EL (2010). Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol), 22, 395-404. https://doi.org/10.1016/j.clon.2010.05.004
- Smallridge RC, Ain KB, Asa SL, et al (2012). American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 22, 1104-39. https://doi.org/10.1089/thy.2012.0302
- Todo T, Martuza RL, Rabkin SD, et al (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA, 98, 6396-401. https://doi.org/10.1073/pnas.101136398
- Vanderpump MP (2011). The epidemiology of thyroid disease. Br Med Bull, 99, 39-51. https://doi.org/10.1093/bmb/ldr030
- Varghese S, Rabkin SD (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther, 9, 967-78. https://doi.org/10.1038/sj.cgt.7700537
- Wang J, Hu P, Zeng M, et al (2011a). Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol, 40, 757-63.
- Wang JN, Hu P, Zeng MS, et al (2011b). Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer, 30, 831-41. https://doi.org/10.5732/cjc.011.10301
- Yu Z, Eisenberg DP, Singh B, et al (2004). Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer, 112, 525-32. https://doi.org/10.1002/ijc.20421
- Zaman M, Fatima N, Sajjad Z, et al (2012). Threshold primary tumour sizes for nodal and distant metastases in papillary and follicular thyroid cancers. Asian Pac J Cancer Prev, 13, 2473-6. https://doi.org/10.7314/APJCP.2012.13.6.2473
- Zeng W, Hu P, Wu J, et al (2013a). The oncolytic herpes simplex virus vector G47 effectively targets breast cancer stem cells. Oncol Rep, 29, 1108-14.
- Zeng WG, Li JJ, Hu P, et al (2013b). An oncolytic herpes simplex virus vector, G47Delta, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep, 29, 2355-61.
피인용 문헌
- MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4937
- The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells vol.35, pp.3, 2016, https://doi.org/10.3892/or.2015.4539
- Oncolytic virus therapy: A new era of cancer treatment at dawn vol.107, pp.10, 2016, https://doi.org/10.1111/cas.13027
- Current status of clinical trials assessing oncolytic virus therapy for urological cancers vol.24, pp.5, 2017, https://doi.org/10.1111/iju.13325
- Oncolytic virotherapy for anaplastic and poorly differentiated thyroid cancer: a promise or a clinical reality? pp.2045-0877, 2018, https://doi.org/10.2217/ije-2017-0028